Perception of biologics/anti-tumour necrosis factor

  • Research type

    Research Study

  • Full title

    To explore the ageing South Asian patients’ perceptions of biologics/anti-tumour necrosis factor (anti-TNF) therapies related to rheumatoid arthritis treatment and satisfaction with information received prior to starting therapy

  • IRAS ID

    221616

  • Contact name

    Kanta Kumar

  • Contact email

    kanta.kumar@manchester.ac.uk

  • Sponsor organisation

    The University of Manchester

  • Duration of Study in the UK

    0 years, 10 months, 1 days

  • Research summary

    Rheumatoid Arthritis (RA) is a condition with no cure and can cause huge disability. Early disease is characterised by pain and other features of inflammation, such as heat, swelling of joints, and loss of function. The risk of developing cardiovascular disease is worse in South Asian RA patients.\n\n \nThere are effective treatments available for RA; however, non-adherence to medicines (not taking medicines as prescribed) is a significant issue in RA. Patients’ perceptions play an important role in adherence to medicines. Our research has showed differences between individuals from ethnic groups on how they view their medicines. These views can potentially impact on medication adherence and patients’ satisfaction with information they receive in clinic. \n\n\nWe have recently shown that South Asian patients with RA were dissatisfied with the information they receive about medicines. Patients’ beliefs about medicines and illness perceptions were found to be associated with satisfaction with information received by clinicians. Furthermore, the British Society of Rheumatology (BSR) led a national audit to survey the delivery of care across UK rheumatology services. In this survey, we found that South Asian patients express greater impact of the disease on functional disability, fatigue, emotional well-being, physical well-being and coping. This can impact on the way patients perceive their disease activity and information received on biologics. \nBiologics treatments in RA are costly and we need to take into account the decisions patients make about these treatments. This project will give us some insight into what type of information is needed in clinics for South Asian patients in order to improve satisfaction with information and adherence. The data collected through this project will help us to develop a template for an audio CD that can be listened to by patients to achieve better understanding of disease and treatments.\n

  • REC name

    North West - Greater Manchester South Research Ethics Committee

  • REC reference

    17/NW/0135

  • Date of REC Opinion

    13 Mar 2017

  • REC opinion

    Further Information Favourable Opinion